시장보고서
상품코드
1429349

세계의 이중 특이성 MAbS 시장 보고서(2024년)

Bi-Specific MAbS Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

이중특이성 MAbS 시장 규모는 향후 몇 년동안 빠르게 성장할 것으로 예상됩니다. 2028년에는 13.3%의 연평균 복합 성장률(CAGR)로 169억 달러 규모에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 암 발병률 증가, 고령화 인구 증가, 만성 질환 증가에 의해 촉진될 것으로 예상됩니다. 이 기간 동안 예상되는 주요 동향으로는 기술 발전, 지속적인 제품 혁신, 인공지능 통합, 표적 치료 및 병용 요법에 대한 투자, 전략적 파트너십 구축에 대한 집중 등이 있습니다.

암 및 기타 만성 질환 증가가 예상됨에 따라 예측 가능한 미래에 이중특이성 단클론항체(MAb) 시장의 성장이 크게 촉진될 것으로 예상됩니다. 이중특이성 단클론항체는 다양한 암, 감염, 중추신경계 질환, 자가면역질환 등 다양한 증상을 치료하기 위해 개발되고 있습니다. 이 항체는 여러 종양 항원을 표적으로 삼는 능력이 특징이며, 암의 진행을 막는 데 있어 기존 단일클론항체(moAb)보다 더 효과적인 것으로 알려져 있습니다. 예를 들어, 미국암학회(ACS)는 2023년 미국에서 암으로 인한 사망자 수가 약 609,820명에 달할 것으로 예상하고 있으며, 이는 만성질환, 특히 암과 효과적으로 싸우기 위한 이중특이성 MAbS의 필요성이 증가하고 있음을 강조하고 있습니다.

의료 연구개발을 위한 정부의 이니셔티브는 이중특이성 MAb 시장의 성장을 가속할 수 있는 여건을 조성하고 있습니다. 이러한 노력에는 의료 문제를 해결하고, 정의된 목표를 달성하거나 긍정적인 사회 변화를 촉진하기 위해 정부 기관이 시행하는 특정 행동, 정책, 프로그램 등이 포함됩니다. 대표적인 예로 미국 보건복지부(HHS)의 한 부서인 생물 의학 첨단 연구 및 개발국(BARDA)과 미국 기반 과학기술 기업인 Regeneron Pharmaceuticals Inc. 미국 보건복지부의 '프로젝트 넥스트젠(Project NextGen)'에 기반한 양사의 협력은 SARS-CoV-2 감염을 예방하기 위한 차세대 단클론 항체 치료제를 개발하는 것을 목표로 합니다. BARDA는 이 치료제에 대한 Regeneron의 임상 개발 비용의 최대 70%를 지원하기로 약속했으며, 계약 금액은 약 3억 2,600만 달러에 달할 것으로 추정되며, 이는 의료 연구개발에 대한 정부 지원의 좋은 예가 될 수 있습니다. 이러한 노력은 진보를 촉진하고 이중특이성 MAbs 시장의 성장에 기여할 것으로 기대됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

  • 세계의 이중특이성 MAbS 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 이중특이성 MAbS 시장 규모 실적과 성장, 2018-2023년
  • 세계의 이중특이성 MAbS 시장 규모와 성장 예측, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 이중특이성 MAbS 시장, 유형별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • Catumaxomab(Removab)
  • Blinatumomab
  • Duligotumab
  • SAR 156597
  • 세계의 이중특이성 MAbS 시장, 제품 유형별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • In Vivo
  • In Vitro
  • 세계의 이중특이성 MAbS 시장, 적응증별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 자가면역 질환
  • 염증성 질환
  • 감염증
  • 미생물 질환
  • 기타
  • 세계의 이중특이성 MAbS 시장, 최종 용도별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원
  • 연구기관
  • 기타

제7장 지역 및 국가별 분석

  • 세계의 이중특이성 MAbS 시장, 지역별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 이중특이성 MAbS 시장, 국가별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 이중특이성 MAbS 시장 경쟁 구도
  • 이중특이성 MAbS 시장 기업 개요
    • F. Hoffmann-La Roche AG
    • Amgen Inc
    • Johnson &Johnson
    • Innovent Biologics
    • Sino Biological Inc

제31장 기타 주요 기업과 혁신 기업

  • Kyowa Kirin
  • Zai Lab
  • Alphamab Oncology
  • Celldex Therapeutics
  • Biocon
  • EpimAb Biotherapeutics
  • ABL Bio
  • Takeda pharmaceuticals
  • Innovent Biologics
  • EpimAb Biotherapeutics
  • Merck &Co Inc
  • Eli Lilly Company Inc.
  • AbbVie Inc
  • Bayer AG
  • Pfizer Inc

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 잠재성 분석

제36장 부록

LSH 24.03.08

Bispecific monoclonal antibodies (BsAbs) feature dual binding sites, strategically designed to target two distinct antigens or epitopes. Unsuch as traditional monoclonal antibodies (MoAbs), BsAbs offer diverse therapeutic applications, making them invaluable in treating various diseases and advancing tumor immunotherapy.

Prominent examples of bispecific monoclonal antibodies include catumaxomab (utilized for malignant ascites treatment), blinatumomab, duligotumab, and SAR 156597. Catumaxomab, a rat-mouse hybrid monoclonal antibody, addresses malignant ascites linked to metastasizing cancer. These innovative antibodies find application in both in vivo and in vitro settings, contributing to the treatment of conditions such as cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and microbial diseases. Hospitals, research institutes, and other healthcare entities leverage bispecific monoclonal antibodies to enhance therapeutic interventions and advance medical research.

The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bi-specific mabs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The expansion observed during the historical period can be ascribed to a surge in healthcare spending, heightened financial support, and proactive government initiatives.

The bi-specific mabs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The anticipated growth in the forecast period is driven by a rising prevalence of cancer, a growing aging population, and an upswing in chronic diseases. Key trends expected in this period encompass a strong emphasis on technological advancements, continuous product innovation, a focus on artificial intelligence integration, investments in targeted and combination therapies, and the establishment of strategic partnerships.

The anticipated rise in cancer and other chronic diseases is poised to significantly bolster the growth of the bispecific monoclonal antibodies (MAbs) market in the foreseeable future. Bispecific monoclonal antibodies are tailored for treating a spectrum of conditions including various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Distinguished by their ability to target multiple tumor antigens, these antibodies are considered more efficacious than conventional monoclonal antibodies (moAbs) in impeding cancer progression. For instance, the American Cancer Society (ACS) projected an estimated 609,820 cancer-related deaths in the USA in 2023, accentuating the increasing need for bi-specific MAbs to effectively combat chronic diseases, notably cancer.

Government initiatives geared towards healthcare research and development are poised to propel the growth of the bispecific MAbs market. These initiatives encompass specific actions, policies, or programs undertaken by governmental bodies to address healthcare challenges, achieve defined objectives, or instigate positive societal changes. An illustrative example involves the collaboration between the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), and Regeneron Pharmaceuticals Inc., a US-based science and technology company. Their collaboration under the U.S. Department of Health and Human Services' 'Project NextGen' aims to develop a next-generation monoclonal antibody therapy for preventing SARS-CoV-2 infection. BARDA's commitment to fund up to 70% of Regeneron's clinical development expenses for this therapy, amounting to an estimated contract value of approximately $326 million, exemplifies governmental support for healthcare research and development. Such initiatives drive advancements and contribute to the growth of the bispecific MAbs market.

Companies within the Bi-Specific MAbS market are increasingly engaging in strategic initiatives, particularly collaborations and partnerships, aimed at expanding their product portfolios and global reach. These collaborations represent cooperative ventures between multiple organizations to achieve shared objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical firm, partnered with MacroGenics, another US-based biopharmaceutical company, in an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3. This initiative, utilizing MacroGenics' DART platform, includes two additional bispecific research programs. Gilead secured an exclusive option to license MGD024, designed to address various hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024's unique design aims to mitigate cytokine-release syndrome (CRS) and facilitate intermittent dosing, potentially enhancing treatment convenience and improving clinical outcomes for AML and MDS patients.

Key players in the Bi-Specific MAbS market are leveraging advanced technologies, particularly bispecific monoclonal antibodies, to gain a competitive edge. These artificial proteins have the capability to simultaneously bind to two different types of antigens, targeting specific molecules on cell surfaces. For instance, in September 2021, Amgen, a US-based biopharmaceutical company, collaborated with Boehringer Ingelheim, a Germany-based pharmaceutical company, on a Phase II-ready project. Encouraging clinicians to transition to bispecific mAbs would require substantial improvements in efficacy or safety. Alternative strategies, such as initiating treatment at an earlier disease stage, modifying administration methods, or adjusting treatment frequency, could be viable but necessitate strategic planning from developers. Bispecific mAbs have the potential not only to outperform competitors but also to potentially impact the market share of CAR-T cell therapies, especially in the relapsed or refractory multiple myeloma segment.

In March 2021, Takeda Pharmaceutical Company Limited, a prominent pharmaceutical company based in Japan, successfully acquired Maverick Therapeutics for an undisclosed sum. This strategic acquisition positions Takeda to advance its capabilities in bispecific antibody technology. The synergy between the two entities is expected to enhance resources and leverage accumulated expertise, thereby accelerating the development of Takeda's T-cell engager platform and expanding its pipeline of innovative bispecific immunotherapies. Maverick Therapeutics, a U.S.-based company specializing in biospecific monoclonal antibodies, brings valuable assets and knowledge to further strengthen Takeda's position in the evolving landscape of immunotherapy.

Major companies operating in the bi-specific mabs market report are F. Hoffmann-La Roche AG, Amgen Inc., Johnson & Johnson, Innovent Biologics, Sino Biological Inc., Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc., Eli Lilly Company Inc., AbbVie Inc., Bayer AG, Pfizer Inc., Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

North America was the largest region in the bi-specific MAbS market in 2023. The regions covered in the bi-specific mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the bi-specific mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bi-Specific MAbS Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bi-specific MAbS market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bi-specific MAbS? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bi-specific MAbS market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Catumaxomab (Removab); Blinatumomab; Duligotumab; Emicizumab; Amivantamab; Faricimab; Teclistamab
  • 2) By Product Type: In Vivo; In Vitro
  • 3) By Indication: Cancer; Hemophilia A; Ophthalmic
  • 4) By End Use: Hospitals; Research Institutes; Other End-Users
  • Companies Mentioned: F. Hoffmann-La Roche AG; Amgen Inc; Johnson & Johnson; Innovent Biologics; Sino Biological Inc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bi-Specific MAbS Market Characteristics

3. Bi-Specific MAbS Market Trends And Strategies

4. Bi-Specific MAbS Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Bi-Specific MAbS Market Size and Growth

  • 5.1. Global Bi-Specific MAbS Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Bi-Specific MAbS Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Bi-Specific MAbS Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Bi-Specific MAbS Market Segmentation

  • 6.1. Global Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Catumaxomab (Removab)
  • Blinatumomab
  • Duligotumab
  • SAR 156597
  • 6.2. Global Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • In Vivo
  • In Vitro
  • 6.3. Global Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cancer
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Microbial Diseases
  • Other Indications
  • 6.4. Global Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Research Institutes
  • Other End-Users

7. Bi-Specific MAbS Market Regional And Country Analysis

  • 7.1. Global Bi-Specific MAbS Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Bi-Specific MAbS Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Bi-Specific MAbS Market

  • 8.1. Asia-Pacific Bi-Specific MAbS Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Bi-Specific MAbS Market

  • 9.1. China Bi-Specific MAbS Market Overview
  • 9.2. China Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Bi-Specific MAbS Market

  • 10.1. India Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Bi-Specific MAbS Market

  • 11.1. Japan Bi-Specific MAbS Market Overview
  • 11.2. Japan Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Bi-Specific MAbS Market

  • 12.1. Australia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Bi-Specific MAbS Market

  • 13.1. Indonesia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Bi-Specific MAbS Market

  • 14.1. South Korea Bi-Specific MAbS Market Overview
  • 14.2. South Korea Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Bi-Specific MAbS Market

  • 15.1. Western Europe Bi-Specific MAbS Market Overview
  • 15.2. Western Europe Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Bi-Specific MAbS Market

  • 16.1. UK Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Bi-Specific MAbS Market

  • 17.1. Germany Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Bi-Specific MAbS Market

  • 18.1. France Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Bi-Specific MAbS Market

  • 19.1. Italy Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Bi-Specific MAbS Market

  • 20.1. Spain Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Bi-Specific MAbS Market

  • 21.1. Eastern Europe Bi-Specific MAbS Market Overview
  • 21.2. Eastern Europe Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Bi-Specific MAbS Market

  • 22.1. Russia Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Bi-Specific MAbS Market

  • 23.1. North America Bi-Specific MAbS Market Overview
  • 23.2. North America Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Bi-Specific MAbS Market

  • 24.1. USA Bi-Specific MAbS Market Overview
  • 24.2. USA Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Bi-Specific MAbS Market

  • 25.1. Canada Bi-Specific MAbS Market Overview
  • 25.2. Canada Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Bi-Specific MAbS Market

  • 26.1. South America Bi-Specific MAbS Market Overview
  • 26.2. South America Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Bi-Specific MAbS Market

  • 27.1. Brazil Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Bi-Specific MAbS Market

  • 28.1. Middle East Bi-Specific MAbS Market Overview
  • 28.2. Middle East Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Bi-Specific MAbS Market

  • 29.1. Africa Bi-Specific MAbS Market Overview
  • 29.2. Africa Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Bi-Specific MAbS Market Competitive Landscape And Company Profiles

  • 30.1. Bi-Specific MAbS Market Competitive Landscape
  • 30.2. Bi-Specific MAbS Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Amgen Inc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Johnson & Johnson
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Innovent Biologics
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sino Biological Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Bi-Specific MAbS Market Other Major And Innovative Companies

  • 31.1. Kyowa Kirin
  • 31.2. Zai Lab
  • 31.3. Alphamab Oncology
  • 31.4. Celldex Therapeutics
  • 31.5. Biocon
  • 31.6. EpimAb Biotherapeutics
  • 31.7. ABL Bio
  • 31.8. Takeda pharmaceuticals
  • 31.9. Innovent Biologics
  • 31.10. EpimAb Biotherapeutics
  • 31.11. Merck & Co Inc
  • 31.12. Eli Lilly Company Inc.
  • 31.13. AbbVie Inc
  • 31.14. Bayer AG
  • 31.15. Pfizer Inc

32. Global Bi-Specific MAbS Market Competitive Benchmarking

33. Global Bi-Specific MAbS Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Bi-Specific MAbS Market

35. Bi-Specific MAbS Market Future Outlook and Potential Analysis

  • 35.1 Bi-Specific MAbS Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Bi-Specific MAbS Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Bi-Specific MAbS Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제